Low Mkt Cap
#32 of 49
$10 B
High CAGR
#12 of 49
25 %
Precision medicine aims to tailor medical treatments to individual patients, based on their genetic, environmental, and lifestyle factors. This approach can help improve treatment outcomes and reduce side effects by providing personalized treatments that are tailored to the patient's specific needs. Precision medicine can also help identify new drug targets and develop more effective therapies for complex diseases, such as cancer and rare genetic disorders.
0 FDA approvals in Precision Medicine
Personalized Treatment
"Precision medicine enables personalized treatment plans that are tailored to the individual patient based on their unique genomic and clinical characteristics, leading to improved patient outcomes." - Nature Reviews Drug Discovery, December 2021
Genomic Analysis
"Precision medicine relies on genomic analysis to identify genetic mutations and biomarkers that can be targeted with specific therapies, enabling more effective and efficient treatment." - The Lancet Oncology, January 2022
Big Data Analytics
"Precision medicine requires the analysis of large amounts of patient data, including genomic, clinical, and environmental factors, which can be facilitated through the use of big data analytics." - Current Opinion in Biotechnology, February 2022
Investor sentiment
Grand View ResearchMay 2021
"...The global precision medicine market size is expected to reach $133.6 billion by 2028, driven by the increasing demand for personalized solutions, the growing adoption of genomics and proteomics technologies, and the rising prevalence of chronic diseases and conditions."
MarketsandResearchMarch 2021
"...The global precision medicine market is projected to grow at a CAGR of over 9% during the period 2021-2028, driven by the increasing focus on personalized and targeted therapies, the growing demand for molecular diagnostics and biomarker testing, and the rising adoption of IT solutions for data integration and analysis."
Sector leaders
Foundation Medicine
Foundation Medicine, a leader in precision oncology, and QIAGEN, a leading global provider of molecular diagnostics and sample preparation technologies, announced they have signed a definitive agreement to enter into a strategic collaboration to develop a complete solution to deliver insights into the molecular basis of cancer. The offering will pair Foundation Medicine's world-class comprehensive genomic profiling (CGP) assays and molecular information solutions with QIAGEN's proven leadership in cancer research and molecular diagnostic development.
Illumina Inc.
Illumina's GRAIL, Inc., a company focused on multi-cancer early detection, announced a strategic partnership with the Prostate Cancer Foundation (PCF) to develop new blood tests for early detection of clinically significant prostate cancer. Through this collaboration, GRAIL and PCF will work to identify promising new targets and clinical biomarkers to detect prostate cancer early, when it is most curable, and potentially avoid unnecessary procedures for patients.
